The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature Full Text
European Urology, 03/19/2012
Sonpavde G et al. – The addition of sipuleucel–T, an immunotherapeutic agent, to the armamentarium represents a paradigm shift in therapy for metastatic castration–resistant prostate cancer. The rational combination and proper sequencing of sipuleucel–T with other newly approved agents and emerging agents will be important to evaluate.